Advancing the Development of an HIV Vaccine for South Africa and Beyond

One of the world’s largest product development partnerships—comprised of the Bill & Melinda Gates Foundation, the US National Institutes of Health, Sanofi Pasteur, GSK, the HIV Vaccine Trials Network and the South African Government—is tackling a formidable challenge: developing the world’s first efficacious HIV vaccine and ensuring it achieves maximum public health impact in South Africa and beyond. This alliance—called the Pox-Protein Public-Private Partnership (P5)—has enlisted Shift Health to help advance priorities and achieve several partnership goals over the course of a multi-year product development plan, including:

Optimizing governance of a complex public-private partnership

Shift Health has worked with senior leaders from P5 member organizations to develop a governance structure that enables cohesive, strategic decision-making and execution of an integrated program plan.

Planning for clinical development outcomes and risks

Through the development of a risk mitigation strategy and contingency planning roadmap, Shift Health is helping to prepare the P5 to respond decisively to scenarios, challenges and milestones throughout the Phase 2b/3 trial.

Ensuring future access to an efficacious HIV vaccine

Shift Health has helped to mobilize and is now working with the P5 Global Access Committee to create an access plan that will guide future deployment of a safe and efficacious vaccine to priority populations in South Africa and beyond.

Maintaining momentum and coordination among partners

As a strategic secretariat, Shift Health advises P5 leadership, helps to engage stakeholders within and external to the P5, and provides ongoing program management support to meet the dynamic needs of a complex partnership.

With a nuanced understanding of the priorities of the P5 and its member organizations, Shift Health’s advisory and program management support is helping the P5 to deliver on its mission to alleviate the burden of HIV/AIDS in South Africa and beyond.

For more information:

• Publication in Current Opinion in HIV and AIDS that describes the P5 governance structure, clinical development plan (including the HVTN 702 Phase 2b/3 trial) and access planning activities
• Shift Health’s perspective on best practices for product development partnerships
• Shift Health’s perspective on best practices for clinical trial scenario planning and risk management